Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Multicenter, prospective, non-interventional study to assess Adherence to treatment for patIeNts with Relapsing Multiple Sclerosis (RMS) who are prescribed subcutaneous (sc) interferon beta-1a	Merck Serono	Ongoing	Interferon Beta-1 a (Rebif)	4	MS200136_0	King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah)
Real World retrospective study of effectiveness and safety of Gilenya (FINgOlimod) in relapsing remitting Multiple Sclerosis in the Middle East and North Africa (FINOMENA)	Novartis	Ongoing	Fingolimod	4	TY720DAE01	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah), King Abdulaziz Hospital Oncology Center, King Fahad Medical City (Riyadh), King Khalid University Hospital (Riyadh), Al-Noor Specialist Hospital (Makkah), Hira Hospital (Makkah), King Fahad Specialist Hospital (Dammam), Dr. Erfan & Bagedo General Hospital (Jeddah)
Does the Addition of Proton Pump Inhibitors to Continuous Enteral Feeding Provide Added Protection Against Upper GI Bleeding in Acutely Ill Patients	KAIMRC	Ongoing	Esmoprozol	4	RC15/079	King Abdulaziz Medical City NG (Riyadh)
A Randomized, Open-label Trial of Paritaprevir Plus Ritonavir Plus Ombitasvir in the Treatment of HCV Genotype 4 Infected Patients with Stage 4-5 Chronic Kidney Disease	Abbvie Biopharmaceuticals GmbH / KSU Liver Disease Research Center	Ongoing	ombitasvir \ paritaprevir \ ritonavir	3	Version 1.3.1	King Abdulaziz Medical City NG (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Hospital (Jeddah)
A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis	Novartis	Ongoing	ofatumumab	3	COMB157G2301	King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
International, randomized, open label study to compare the safety and efficacy of lixisenatide vs sulfonylurea on top of basal insulin treatment in Type 2 Diabetes Mellitus subjects who elect to fast during Ramadan	Sanofi	Terminated	Lixisenatide	3	LPS14410	King Khalid University Hospital (Riyadh)
"Open-label, multicenter, single arm, phase II study assessing treatment patient preference for new deferasirox formulation (film-coated tablet) compared to the reference deferasirox dispersible tablet formulation"	Novartis	Ongoing	deferasirox	2	CICL670FIC05	King Abdulaziz University Hospital (Jeddah), Hereditary Blood Disease Center (al ahsa), King Abdulaziz Medical City NG (Riyadh)
A Phase II Study to examine the efficacy and safety of a new drug called Sevuparin on resolution of painful vaso-occlusive crisis in patients with sickle-cell disease.	Dilaforette AB	Ongoing	Sevuparin	2	TVOC01	King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), Qatif Central Hospital
Multicenter Inetrnational neoadjuvant randomized double-blind trial comparing fulvestrant to a combination of fulvestrant and palcociclib in patients with operable luminal breast cancer responding to fulvestrant	ICR Group - International Cancer Research group	Ongoing	palbociclib fulvestrant	3	ICRG 1201	King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz University Hospital (Jeddah)
A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL STUDY EVALUATING THE EFFICACY AND SAFETY OF USING TOCILIZUMAB (TCZ) FOR CONFIRMED RHEUMATOID ARTHRITIS (RA) PATIENTS IN CLINICAL PRACTICE	Roche	Ongoing	tocilizumab	4	ML299336	King Khalid University Hospital (Riyadh), King Fahad Medical City (Riyadh)